A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers
Clinical trial NCT06496568 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06496568
- Sponsor
- Hoffmann-La Roche
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-11
- Primary completion
- 2027-07-21
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.